Drug Profile
Potassium bicarbonate/potassium citrate - Advicenne
Alternative Names: ADV 7103; Potassium citrate monohydrated/potassium hydrogen carbonate; Potassium citrate/potassium bicarbonate; Potassium hydrogen carbonate/potassium citrate monohydrated; Potassium-bicarbonate/potassium-citrate-Advicenne; SibnayalLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Advicenne
- Class Alkalinising agents; Citrates; Electrolytes; Potassium compounds; Small molecules; Urologics
- Mechanism of Action Electrolyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Kidney disorders
Highest Development Phases
- Marketed Kidney disorders
- Phase II/III Cystinuria
Most Recent Events
- 12 Mar 2024 Advicenne Pharma withdraws a phase II/III trial in Cystinuria (In infants, In children, In adolescents, In adults, In the elderly) prior to enrollment in Belgium and France due to unspecified business decision (NCT04137978) (EudraCT2017-002068-42)
- 08 Mar 2024 Advicenne Pharma withdraws an extension to phase IIIb ARENA 2 trial for Kidney disorders (distal renal tubular acidosis) (In infants, In children, In adolescents, In adults) in USA (PO) due to completion of long term safety study in the EU (NCT03831152)
- 08 Mar 2024 Advicenne Pharma terminates the phase IIIARENA-2 trial in Kidney disorders (In adolescents, In children, In infants, In adults) in Canada, USA (PO) due to requirement of design review in discussion with US FDA (NCT03644706)